Influence of dapagliflozin on cardiovascular remodeling in hypertensive patients with accompanying type 2 diabetes

被引:0
|
作者
Bohun, A. O. [1 ]
机构
[1] Zaporizhzhia State Med & Pharmaceut Univ, Dept Propaedeut Internal Med Radiat Diagnost & Rad, Zaporizhzhia, Ukraine
来源
PATHOLOGIA | 2024年 / 21卷 / 01期
关键词
dapagliflozin; SGLT2; inhibitors; vascular; stiffness diastolic; dysfunction; hypertension type; 2; diabetes; HEART-FAILURE; ARTERIAL STIFFNESS; DIASTOLIC FUNCTION; GUIDELINES; MELLITUS; PROFILE; IMPACT;
D O I
10.14739/2310-1237.2024.1.299196
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Aim. To compare the results of 12-week treatment of patients with stage II hypertension (HTN) with accompanying diabetes mellitus (DM) type 2 between the combination of metformin + dapagliflozin and metformin monotherapy by studying changes the elastic properties of the common carotid arteries (CCA), echocardiographic indicators, 24-hour ambulatory blood pressure monitoring (ABPM) and laboratory parameters of lipid and carbohydrate metabolism. Materials and methods. 24 patients with stage II HTN with type 2 DM were involved in the study, the average age 60.4 years, 50 % - men. Patients in the first group were randomized to receive metformin, and the second group - to receive combination of metformin and dapagliflozin. At inclusion and after 3 months of treatment, basic anthropometric data, laboratory indicators of lipid and carbohydrate metabolism, ABPM, echocardiography, and indicators of CCA local stiffness were studied. Statistical analysis was performed, the probability of differences is at the level of p < 0.05. Results. In both observation groups, there was a comparable decrease in SCORE 2 -Diabetes range, glucose and glycated hemoglobin, total cholesterol, LDL cholesterol, average daily systolic blood pressure (SBP), daily SBP load, day and pulse BP, as well as an increase in speed systolic movement of the lateral fibrous ring of the mitral valve (S lat). Only in the metformin + dapagliflozin group a decrease in the adipose tissue level, the average daily diastolic blood pressure (DBP), the burden of DBP, the size of the left atrium and right ventricle, an increase in the movement speeds of the medial (e'med), lateral (e'lat) ring of the mitral and of the tricuspid (e'tk) valve in the period of early diastolic filling of the ventricles, velocities of systolic movement of the medial fibrous ring of the mitral (S med) and tricuspid (S tk) valves, a decrease ratio E/e', and an improvement in the elastic properties of general carotid arteries were observed. Conclusions. In persons with HTN stage II with DM type 2 the addition of dapagliflozin to the treatment regimen was associated with better control of blood pressure, improvement of diastolic function and longitudinal contractility of the left ventricle, elastic properties of CCA.
引用
收藏
页码:41 / 50
页数:10
相关论文
共 50 条
  • [1] Dapagliflozin and cardiovascular outcomes in patients with Type 2 diabetes
    Al-Bazz, Dalai Y.
    Wilding, John P. H.
    [J]. FUTURE CARDIOLOGY, 2020, 16 (02) : 77 - 88
  • [2] Cardiovascular Outcomes with Dapagliflozin for Patients with Type 2 Diabetes
    Pavlicek, Vojtech
    [J]. DIABETOLOGE, 2019, 15 (03): : 262 - 264
  • [3] Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
    Wiviott, S. D.
    Raz, I.
    Bonaca, M. P.
    Mosenzon, O.
    Kato, E. T.
    Cahn, A.
    Silverman, M. G.
    Zelniker, T. A.
    Kuder, J. F.
    Murphy, S. A.
    Bhatt, D. L.
    Leiter, L. A.
    McGuire, D. K.
    Wilding, J. P. H.
    Ruff, C. T.
    Gause-Nilsson, I. A. M.
    Fredriksson, M.
    Johansson, P. A.
    Langkilde, A-M.
    Sabatine, M. S.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (04): : 347 - 357
  • [4] Dapagliflozin and measures of cardiovascular autonomic function in patients with type 2 diabetes
    Ang, L.
    Kidwell, K.
    Dillon, B.
    Reiss, J.
    Leone, V.
    Mizokami-Stout, K.
    Busui, R.
    [J]. DIABETOLOGIA, 2020, 63 (SUPPL 1) : S406 - S406
  • [5] Dapagliflozin and Measures of Cardiovascular Autonomic Function in Patients with Type 2 Diabetes
    Ang, Lynn
    Kidwell, Kelley M.
    Reiss, Jacob
    Dillon, Brendan R.
    Mizokami-Stout, Kara R.
    Leone, Virginia A.
    Pop-Busui, Rodica
    [J]. DIABETES, 2020, 69
  • [6] Dapagliflozin lowers blood pressure in hypertensive and non-hypertensive patients with type 2 diabetes
    Sjostrom, C. David
    Johansson, Peter
    Ptaszynska, Agata
    List, James
    Johnsson, Eva
    [J]. DIABETES & VASCULAR DISEASE RESEARCH, 2015, 12 (05): : 352 - 358
  • [7] Dapagliflozin preserves renal vasodilating capacity in hypertensive patients with type 2 diabetes
    Bruno, R.
    Giannini, L.
    Dardano, A.
    Biancalana, E.
    Seghieri, M.
    Taddei, S.
    Ghiadoni, L.
    Solini, A.
    [J]. DIABETOLOGIA, 2018, 61 : S315 - S316
  • [8] Dapagliflozin lowers blood pressure in hypertensive and nonhypertensive patients with type 2 diabetes
    Sjostrom, D.
    Johansson, P.
    Ptaszynska, A.
    List, J.
    Johnsson, E.
    [J]. DIABETOLOGIA, 2014, 57 : S332 - S333
  • [9] Diabetes meliitus contributes to cardiovascular remodeling in hypertensive patients
    Falkovskaya, A.
    Mordovin, V.
    Belokopytova, N.
    Tsimbalyuk, E.
    [J]. JOURNAL OF HYPERTENSION, 2008, 26 : S196 - S196
  • [10] Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes Reply
    Wiviott, Stephen D.
    Raz, Itamar
    Sabatine, Marc S.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (19): : 1881 - 1882